Immunome, Inc. (IMNM)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 14 | 9 | 7 | - | - |
| Operating profit | $m | -214 | - | ||||||
| Net profit | $m | -18 | -25 | -37 | -107 | -293 | -212 | - | -190 |
| EPS reported | $ | -2.43 | - | ||||||
| Operating cashflow per share | $ | -2.19 | - | ||||||
| Capex per share | $ | 0.11 | - | ||||||
| FCF per share | $ | -2.30 | - | ||||||
| Free cash flow | $m | -201 | - | ||||||
| Net debt | $m | -650 | - | ||||||
| Book value equity | $m | 634 | - | ||||||
| Book value per share | $ | 7.26 | - | ||||||
| Number of shares | m | 87.35 | - | ||||||
| DPS (TTM paid) | $ | 0.00 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 2.96 | - | ||||||
| P/S LTM | x | 270.32 | - | ||||||
| P/FCF LTM | x | -9.35 | - | ||||||
| EV/EBITDA LTM | x | -5.86 | - | ||||||
| EV/Sales LTM | x | 176.73 | - | ||||||
| Earnings Yield LTM | % | -11.32% | - | ||||||
| FCF Yield | % | -10.69% | - | ||||||
| Quality | |||||||||
| ROE | % | -33.48% | - | ||||||
| ROIC | % | -33.55% | - | ||||||
| Operating margin | % | -30.85% | - | ||||||
| Gross margin | % | +57.43% | - | ||||||
| FCF/Sales | % | -2890.1% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -23.23% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -52.04 | - | ||||||
| Net Debt/EBITDA | x | 3.10 | - | ||||||
| EBIT/Net interest | x | 0.00 | - | ||||||
| Net debt/market cap | % | +0.21% | - | ||||||
| Net debt/Equity | x | -1.02 | - | ||||||
| Gross debt/equity | x | 0.01 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free